COMy 2023 | Strategies to optimize CAR-T therapy in myeloma: bringing CAR-T into earlier lines
Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses possible strategies to optimize CAR-T therapy in patients with multiple myeloma. Despite the promise of these agents, many patients relapse after treatment with CAR-T cells, emphasizing the need to improve outcomes. Prof. Delforge comments on the possibility of bringing CAR-T cells into earlier lines and highlights trials exploring this, including KarMMa-3 (NCT03651128) and CARTITUDE-4 (NCT04181827). This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
